# EDGAR Filing Document

**Accession Number:** 0001938571
**File Stem:** 0000000000-25-007475
**Filing Date:** 2025-7
**Character Count:** 4735
**Document Hash:** 0c032dd031ca706784c507d8be7b4908
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007475.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0000000000-25-007475

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250716

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADAPTIN BIO, INC.
- **CENTRAL INDEX KEY:** 0001938571
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 881566415
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-287338

**BUSINESS ADDRESS:**
- **STREET 1:** 3540 TORINGDON WAY
- **STREET 2:** SUITE 200, #250
- **CITY:** CHARLOTTE
- **STATE:** NC
- **ZIP:** 28277
- **BUSINESS PHONE:** (888) 609-1498

**MAIL ADDRESS:**
- **STREET 1:** 3540 TORINGDON WAY
- **STREET 2:** SUITE 200, #250
- **CITY:** CHARLOTTE
- **STATE:** NC
- **ZIP:** 28277

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Unite Acquisition 1 Corp.
- **DATE OF NAME CHANGE:** 20220719
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-25-044585

## Text-Extract

```

                                                            July 16, 2025

Michael J. Roberts
President and Chief Executive Officer
Adaptin Bio, Inc.
3540 Toringdon Way, Suite 200, #250
Charlotte, NC 28277

       Re: Adaptin Bio, Inc.
           Amendment No. 1 to Registration Statement on Form S-1
           Filed June 27, 2025
           File No. 333-287338
Dear Michael J. Roberts:

     We have reviewed your amended registration statement and have the
following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our June 13,
2025 letter.

Amendment No. 1 to Registration Statement on Form S-1
About This Prospectus, page ii

1.     We note your response to prior comment 19 and your removal of references
to
       exhibits incorporated by reference. Please revise your prospectus
further to remove all
       references to information incorporated by reference, including in this
section and on
       page 43.
Business of the Company
Our Product Pipeleine
APTN-101, page 39

2.     We note your response to prior comment 2 and your revised disclosure
removing
       certain performance claims as well as statements indicating or
suggesting that your
 July 16, 2025
Page 2

       product candidate is safe and/or effective. We continue to note your
disclosure on
       page 42 that the BRiTE technology has an "acceptable safety profile."
Please revise or
       remove this statement as safety and efficacy determinations are within
the exclusive
       purview of FDA and other similar foreign regulators.
General

3.     We continue to consider your response to prior comment 20. Please also
tell us
       whether the merger was submitted for a shareholder vote or consent. In
that regard,
       we note that Section 2.3 of the Agreement and Plan of Merger and
Reorganization
       appears to indicate that the merger was approved    by the vote of
Company
       Stockholders required by the DGCL and the Company   s by-laws.    If
there was such a
       vote or consent, it appears that the affiliates of Adaptin Bio, Dr.
Pedder, Dr. Roberts,
       and Duke University, are deemed to be underwriters pursuant to
Securities Act Rule
       145(c).
4.     We note your response to prior comment 21. Please revise to specify a
single price at
       which the selling shareholders will offer and sell their shares until
your common stock
       is quoted on the OTCQB or OTCQX market or listed on a national
securities
       exchange.
       Please contact Gary Newberry at 202-551-3761 or Kevin Vaughn at
202-551-3494 if
you have questions regarding comments on the financial statements and related
matters. Please contact Joshua Gorsky at 202-551-7836 or Joe McCann at
202-551-6262 with
any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Jonathan A. Greene, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._